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Abst ract
Background and purpose: Reoperations of patients with recur-
rent low-grade gliomas (LGG) are not always recommended
due to a higher risk of neurological deficits when compared to
initial surgery. The purpose of the present study was to evaluate
surgical outcomes of patients operated on for recurrent LGG.
Material and methods: Sixteen patients who had surgery for
recurrent LGG out of 68 LGG patients who underwent
surgery at the Department of Neurosurgery in Sosnowiec,
Poland between 2005 and 2011 were enrolled in the study.
Results: A large tumour volume prior to the initial surgery
was the most significant parameter influencing LGG pro-
gression (96.6 cm3 vs. 47.9 cm3, p = 0.01). Increased inci-
dence of epileptic seizures and decreased mental ability ac -
cording to Karnofsky score were the most common symptoms
associated with tumour recurrence. In the group of patients
with malignant transformation, the relative cerebral blood
volume (rCBV) was considerably increased (1.21 vs. 2.41, 
p < 0.01). No statistically significant difference was found
in terms of the extent of resection between initial surgery and
reoperation. Similarly, no significant difference was found in
the number of patients with a permanent neurological deficit
after initial surgery and reoperation. 
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St reszc zenie
Wstêp i cel pracy: Ponowne operacje chorych z odrostem
wysoko zró¿nicowanego glejaka mózgu (WGM), zw³aszcza
zlokalizowanego w obszarach elokwentnych mózgu, nie zaw -
sze s¹ zalecane. Powodem tego jest przekonanie, ¿e ryzyko
wyst¹pienia deficytów neurologicznych jest wiêksze ni¿ pod-
czas pierwszej operacji. Celem pracy by³a ocena wyników
leczenia chorych operowanych ponownie z powodu odrostu
WGM.
Materia³ i metody: W okresie od 2005 r. do 2011 r. w Klinice
Neurochirurgii w Sosnowcu operowanych by³o 68 chorych
z rozpoznaniem WGM. Do analizy w³¹czono 16 chorych ope-
rowanych ponownie z powodu odrostu guza.
Wyniki: Jednym z najistotniejszych parametrów decyduj¹cych
o progresji WGM by³a du¿a objêtoœæ guza przed pierwsz¹
operacj¹ (96,6 cm3 vs 47,9 cm3; p = 0,01). G³ównym objawem
odrostu guza by³a zwiêkszona czêstoœæ napadów padaczko-
wych oraz pogorszenie sprawnoœci intelektualnej ocenianej
w skali Karnofsky’ego. Wœród guzów, w przypadku których
dosz³o do zez³oœliwienia odrostu, obserwowano istotny wzrost
wzglêdnej mózgowej objêtoœci krwi (rCBV) (1,21 vs 2,41; 
p < 0,01). Nie stwierdzono statystycznie istotnej ró¿nicy pod
wzglêdem doszczêtnoœci resekcji miêdzy pierwsz¹ i ponown¹
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Introduction
Low-grade gliomas (LGG), despite the fact that they
are histologically benign, tend to undergo malignant
transformation which significantly shortens the patient’s
lifespan. The most important factors that affect LGG
patients’ survival include age, the extent of resection,
histological type and initial volume of the tumour [1-12].
Recent years have brought a number of publications,
which stress that the extent of resection is a significant,
independent factor that affects overall survival and pro-
gression-free survival (including time to malignant trans-
formation) of patients after surgery for LGG [1,6,9,
10,12]. Importantly, the introduction of neuronaviga-
tion, functional MRI and intraoperative neurophysio-
logical monitoring facilitated the extension of resections
of LGG that occupy eloquent areas, mainly motor cor-
tex and speech areas, while allowing the preservation of
permanent, iatrogenic neurological deficits within
acceptable limits [9,13-19]. Still, for most of the LGG
located within eloquent brain areas only partial resec-
tion is feasible [9,13,14,20,21]. The decision to leave
a part of the tumour within an eloquent area is usually
made based on neuronavigation and neurophysiologi-
cal monitoring indications in order to avoid new, severe
and permanent neurological deficits that might be 
rendered by extended resection. Interestingly, while the
benefits of extensive initial resection of LGG raise no
doubts, still the indications for reoperation of recurrent
LGG are a matter of debate. Scepticism arises mainly
from the conviction that the risk of injury is even greater
with reoperation. Some authors advise that pa tients with
recurrent tumour should undergo chemo- or radio-
therapy instead [1,22-26].
The aim of our prospective, observational case study,
based on a series of patients previously diagnosed with
LGG, was to evaluate the surgical outcome of secondary
surgery for recurrent tumour.
Material and methods
Sixty-eight patients who underwent surgery for WHO
grade II LGG [27] in the Department of Neurosurgery
of the Silesian Medical University in Sosnowiec between
January 2005 and July 2011 were included in our study.
Subsequent analysis involved 16 patients (24%) who were
reoperated on for recurrent tumour. Cases with any dia -
meter enlargement and/or new contrast enhancement in
the tumour remnants in follow-up magnetic resonance
imaging (MRI) in FLAIR sequence at least 3 months
after the initial surgery were considered recurrent.
Patients prior to initial as well as secondary surgery
underwent a series of imaging studies that involved
MRI with T1- and T2-weighted and FLAIR sequences
along with functional (BOLD-fMRI), diffusion-ten-
sor imaging (DTI) and perfusion (PWI) studies. Per-
fusion data were subsequently used to calculate relative
cerebral blood volume (rCBV), a quotient of maximal
CBV within the lesion to CBV in normal white matter
in the contralateral hemisphere. Tumour volume was
calculated based on FLAIR images. According to the
classification proposed by Sawaya et al. [28], anatomical
regions occupied by tumours were subsequently divid-
ed into non-eloquent brain, near-eloquent brain and elo-
quent brain. All operations were performed with neu-
ronavigation (BrainLab AG, Munich, Germany). All
the patients with tumours within or near the sensori-
motor cortex or motor speech representation addition-
Conclusions: Reoperations of the patients with recurrent LGG
are not burdened with a higher risk of neurological sequelae
when compared to initial surgery. The extent of resection
during the surgery for LGG recurrence is comparable to ini-
tial surgery. The increase of rCBV seems to be a significant
biomarker that indicates malignant transformation.
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operacj¹. Nie stwierdzono statystycznie istotnej ró¿nicy w licz-
bie chorych z utrwalonym deficytem neurologicznym po 
pierwszym zabiegu i po ponownej operacji. 
Wnioski: Ponowne operacje chorych z odrostem WGM, rów-
nie¿ tych zlokalizowanych w obszarach elokwentnych mózgu,
nie s¹ obarczone wiêkszym ryzykiem powik³añ neurologicz-
nych w porównaniu z pierwsz¹ operacj¹. Stopieñ resekcji
osi¹gany przy operacjach odrostu WGM jest porównywalny
z zakresem resekcji po pierwszej operacji. Istotnym parame-
trem wskazuj¹cym na zez³oœliwienie procesu nowotworowego
jest wzrost rCBV.
S³owa kluczowe: glejaki wysoko zró¿nicowane, progresja no -
wotworu, reoperacja, wzglêdna mózgowa objêtoœæ krwi.
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ally went through functional imaging studies in order
to visualize active regions within eloquent areas of cor-
tex and white matter tracks. All the patients with tu -
mours in the vicinity of the motor cortex had motor
evoked potentials (MEP) monitored during surgery.
MEP monitoring involved transcranial stimulation
(TES), direct cortical stimulation (DCS) and direct sub-
cortical white matter stimulation (DSCS). All electro-
physiological studies were performed with Inomed ISIS
apparatus (Teningen, Germany) with the “train” sti-
mulation pattern (4 to 6 single 0.5-ms stimuli with 3 to 
4 ms intervals). Current of a few to several mA (3-30 mA
range) was used for DCS and DSCS and current of 100
to 150 mA (max. 220 mA) for TES was used.
Postoperative MRI was performed within 48 hours
after surgery. The extent of resection was evaluated bas -
ed on pre- and postoperative FLAIR images. Accord-
ing to Sawaya et al. [28], the extent of resection was clas-
sified as gross total (> 95%), subtotal (85-95%) and
partial (< 85%).
Follow-up imaging studies were performed in 
6-month intervals and involved T1- and T2-weighted
images, FLAIR sequences, MR spectroscopy (MRS)
and PWI studies. Intellectual performance and patient
independence were assessed with the Karnofsky perfor-
mance scale (KPS). Neurological examination involved
assessment of seizures and headaches frequency along
with neurological deficits (hemiparesis, speech distur-
bances and hemianopsia) evaluation. Deficits that sub-
sided within 3 months after surgery were considered
transient while those that lasted more than 3 months
were deemed permanent.
Statistical analysis
Statistical analysis was performed with the STATIS-
TICA 9.0 software package (StatSoft, USA). Distribu-
tion of quantitative variables was primarily evaluated with
the Shapiro-Wilk test. Variables were cha racterized with
median and interquartile range values. For statistical
analysis, Mann-Whitney U-test or Student t-test were
used based on variable distribution. For qualitative vari-
ables, intergroup differences were evaluated with the χ2
test (with Yates correction for small groups). Results of
pre- and postoperative studies were compared with non-
parametric Wilcoxon pair-rank test or Student t-test for
dependent variables. For all of the analyses, the signifi-
cance level was set at 0.05. Kaplan-Meier analysis was
used for calculation of survival curves and for assessment
of predictive values of evaluated variables.
Results
In our cohort of 68 patients operated on for LGG,
we found 22 cases of progression (32%) that included
11 patients (16%) with malignant transformation. Me -
dian follow-up time for all of the patients was 34 months
(interquartile range: 21-49 months). Five-year progres -
sion-free survival for all of the patients was 35%; accord-
ingly, malignant transformation-free survival was 53%.
Sixteen patients underwent reoperation, three patients
died from progression, and three other patients opted
against surgery and remain in a stable neurological con-
dition.
Our cohort of 16 patients who were reoperated on
in cluded 8 men aged 24 to 59 years and 8 women aged 
24 to 48 years (median age for all of the patients was 
34 years with interquartile range of 29-42 years). Over-
all performance assessed with KPS prior to the initial
surge ry for the majority of the patients, i.e. 13 patients
(82%), was either 90 or 100 points. Eleven patients
(69%) had tumours localized in one of the brain elo-
quent areas (the most common location being the motor
cortex), 4 (25%) of them in near-eloquent areas and 
1 patient (6%) outside eloquent areas. Median preop-
erative tumour volume was 96.6 cm3 (interquartile
range, 75.4-168 cm3). Importantly, in the remaining 
46 patients who underwent surgery for LGG in the
Fig. 1. Comparison of tumour volumes prior to initial surgery in 16 patients
who underwent reoperation and 46 patients without reoperation (p = 0.01)
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same period and showed no signs of recurrence, medi-
an preoperative tumour volume was 47.9 cm3 (interquar-
tile range, 27.1-98.4 cm3). The difference in tumour
volumes between these groups was statistically signifi-
cant (p = 0.01) (Fig. 1). During initial surgery, none of
the 16 patients had gross total resection. Subtotal resec-
tion was achieved in 3 patients (19%) while the remain-
ing 13 patients (81%) had partial resection. Fourteen
patients (88%) had histopathological diagnosis of fib-
rillary astrocytoma, one patient (6%) had oligoastrocy-
toma and one other (6%) had oligodendroglioma. Two
patients developed permanent neurological deficits after
surgery.
Median time between initial surgery and reopera-
tion was 19 months (interquartile range, 15-33 months).
The increased incidence of seizures, found in 7 patients
(50%), was the most common symptom of tumour re -
currence. The extent of resection after reoperation was
assessed as gross total in 1 patient (7%), in 4 others as
subtotal (27%) and in the remaining 10 patients (66%)
as partial. For technical reasons, one of the patients had
no postoperative MRI, i.e. analysis of the extent of resec-
tion after secondary surgery was performed in 15 cases.
Postoperative histopathological diagnoses were as fol-
lows: 6 patients (38%) had LGG WHO grade II while
the remaining 10 patients (62%) had either WHO grade
III or IV tumours. Five patients (36%) developed per-
manent neurological deficits after secondary surgery.
Tables 1 and 2 summarize comparisons of selected
clinical and radiological data between the groups of pa -
tients with either grade II or grade III/IV tumours. No -
tably, we found a statistically significant deterioration of
intellectual performance and independence assessed with
KPS prior to reoperation in patients with malignant
transformation (WHO grade III or IV) when compared
to the patients without malignant transformation (Table 1).
Moreover, patients with malignant transformation show -
ed significantly higher rCBV values (Table 2). No dif-
ferences in the extent of resection between patients with
grade II and III/IV tumours during primary as well as
secondary surgery were found (Table 2).
Accordingly, Table 3 presents comparisons of select-
ed clinical and radiological data between primary and
secondary surgery in our group of 16 patients analysed.
Importantly, no significant differences in numbers of
patients with permanent neurological deficits after pri-
mary and secondary surgery were found. Similarly, we
found no significant differences in volumes of tumours
after primary and secondary surgery in patients with
either recurrent grade II tumours, with malignant trans-
formation of the tumour, or in the entire group with
recurrent LGG. No statistically significant differences
were found with regard to the extent of resection between
primary and secondary surgery while rCBV values in the
group of patients with malignant transformation were
significantly higher prior to reoperation when compared
to the values prior to the primary surgery.
Discussion
Twenty-two patients (32%) out of 68 patients who
underwent surgery for LGG between 2005 and 2011
showed signs of tumour progression, i.e. 5-year pro-
gression-free survival in our group was 35%. Various
authors have reported progression-free survival values
between 19% [11] and 55% [2], but in the majority it
approximates 50% [1,4,5,7,12,29,30]. Median for the
time free from progression in patients treated for LGG
varies between 2 [31-33] and 5.5 years [10] but again
the majority of authors report 5 years [5,6,21]. The most
important factors that significantly increase progression-
free survival include: age (≤ 40 years) [12], histopathol-
ogy of the tumour (oligodendroglioma/oligoastrocytoma
vs. astrocytoma) [5], preoperative volume of the tumour
[1,10,30], postoperative volume of the tumour [10,30]
and the extent of resection [6,12,33]. In our cohort of
16 patients, median progression-free survival time was
relatively short at 19 months (interquartile range, 15 to
33 months), a value close to the one reported by Schmidt
et al. [33]. These authors, however, found a significant
relationship between progression-free survival and the
extent of resection. In patients with gross total resection
(> 90%), median time to reoperation was 49 months
while in those with subtotal resection it was only 
25 months. In our group all of the patients who under-
went reoperation had either subtotal or partial resection
of the tumour and a vast majority of them (88% of pa -
tients) had a final diagnosis of fibrillary astrocytoma.
Moreover, prior to the first surgery the volume of the
tumours in this group was significantly higher when
compared to the remaining 46 patients treated for LGG.
LGG progression in our study cohort was related then
to subtotal resection, histopathological diagnosis of astro-
cytoma and finally to the size of the tumour.
A significant fraction of LGGs undergo malignant
transformation to WHO grade III or IV tumours. Var-
ious studies report the percentage of malignant trans-
formations varying from 13 to 86% [1,6,8,10,21,31,32,
34-36]. Here we report that 50% of our patients with
radiological signs of progression had malignant trans-
Reoperations of patients with low-grade gliomas
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formation. In 16 patients who were reoperated on, this
value was even higher, at 62%. Smith et al. [10] report-
ed that the most important risk factor for malignant
transformation is a large preoperative volume of the
tumour. McGirt et al. [6], on the other hand, proved
that patients after gross total resection survive longer
Variable WHO grading after surgery Total P-value
grade II grade III/IV (grade II vs. III/IV)*
No. of patients (%) 6 (38) 10 (62) 16 (100)
Age [years] 38 (33-48) 33 (27-36) 34 (29-42) NS#
Sex
Female 4 (66%) 4 (40%) 8 (50%) NS
Male 2 (34%) 6 (60%) 8 (50%)
Side; n (%)
Left 5 (83) 5 (50) 10 (63) NS
Right 1 (17) 5 (50) 6 (37)
Time to secondary surgery [months] 19 (4-37) 19 (11-28) 19 (15-33) NS#
KPS score prior to initial surgery
70 1 (17%) 1 (10%) 2 (12%) NS
80 0 (0%) 1 (10%) 1 (6%)
90 1 (17%) 2 (20%) 3 (19%)
100 4 (66%) 6 (60%) 10 (63%)
Symptoms prior to initial surgery
Headache 1 (17%) 3 (30%) 4 (25%) NS
Epilepsy 5 (83%) 9 (90%) 14 (88%) NS
Neurological deficits 2 (34%) 4 (40%) 6 (37%) NS
Permanent neurological deficit after initial surgery 1 (17%) 1 (10%) 2 (12%) NS
KPS score prior to secondary surgery
70 3 (50%) 0 (0%) 3 (19%) < 0.05
80 0 (0%) 5 (50%) 5 (31%)
90 2 (33%) 5 (50%) 7 (44%)
100 1 (17%) 0 (0%) 1 (6%)
Symptoms prior to secondary surgery**
Headache 2 (34%) 2 (25%) 4 (29%) NS
Epilepsy 1 (20%) 6 (67%) 7 (50%) NS
Neurological deficits 2 (40%) 2 (22%) 4 (29%) NS
Permanent neurological deficit after secondary 2 (40%) 3 (33%) 5 (36%) NS
surgery**
Radiotherapy 3 (50%) 8 (80%) 11 (69%) NS
Table 1. Comparison of selected variables between patients with WHO grade II and WHO grade III/IV among 16 patients operated on for low-grade glioma 
recurrence – data are reported as n (%) or median (interquartile range)
*P-values for χ2 test with Yates correction, except for those indicated with # (Student t-test).
**Patients with permanent deficits after initial surgery that did not regress were excluded.
NS – non-significant; KPS – Karnofsky Performance Scale
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without malignant transformation when compared to
patients after subtotal or partial resection. Lastly, Chai -
chana et al. [1], based on multifactor analysis, reported
histopathological diagnosis of fibrillary astrocytoma, size
of the tumour and the extent of resection as the most
important risk factors for LGG malignant transforma-
tion with tumours ≥ 3 cm in diameter at the highest risk
of malignant transformation. Im portantly, gross total
resection significantly lowered that risk. Medians for
the time free from malignant transformation according
to Smith et al. [10], McGirt et al. [6] and Schmidt et
al. [33] were 10.1 years, 8.8 years and 47 months (range
from 6 to 88 months), respectively. Ac cording to Chai -
chana et al. [1] 5-year malignant transformation-free
survival was 74% while in our group it was 53%.
The occurrence of contrast enhancement in the 
follow-up MRI suggests malignant transformation. 
Ac cording to Schmidt et al. [33] the occurrence of con-
trast enhancement within the tumour has 65% sensitiv-
ity and 80% specificity for malignant transformation.
Variable WHO grading after surgery Total P-value
grade II grade III/IV (grade II vs. III/IV)*
Tumour volume prior to initial surgery [cm3] 100.9 96.6 96.6 NS
(73.6-219.5) (77.3-127.7) (75.4-168.0)
rCBV prior to initial surgery 1.28 1.96 1.60 NS
(1.11-1.71) (1.27-2.61) (1.11-2.40)
Contrast enhancement prior to initial surgery
Yes 1 (17%) 5 (50%) 6 (37%) NS#
No 5 (83%) 5 (50%) 10 (63%)
Tumour volume after initial surgery [cm3] 50.1 35.0 35.0 NS##
(13.8-121.3) (20.5-52.4) (17.9-67.4)
% of resection after initial surgery 7770.8 (45-88) 70.8 (41.0-78.2) 74 (43-83) NS
Resection degree after initial surgery
Gross total 0 (0%) 0 (0%) 0 (0%) NS#
Subtotal 2 (34%) 1 (10%) 3 (19%)
Partial 4 (66%) 9 (90%) 13 (81%)
Tumour volume prior to secondary surgery [cm3] 93.5 58.9 76.2 NS
(74.4-229.8) (40.9-113.9) (44.2-120.4)
rCBV prior to secondary surgery 1.21 (1.01-1.50) 2.41 (1.66-2.91) 1.81 (1.29-2.67) < 0.01##
Contrast enhancement prior to secondary surgery
Yes     3 (50%) 7 (70%) 10 (63%) NS#
No 3 (50%) 3 (30%) 6 (37%)
Tumour volume after secondary surgery* [cm3] 22.2 36.2 24.1 NS
(14.3-88.0) (18.2-74.7) (14.3-88.0)
% of resection after secondary surgery** 79 (54-86) 62 (12-70) 70 (41-89) NS##
Resection degree after secondary surgery**
Gross total 0 (0%) 1 (11%) 1 (7%) NS# 
Subtotal 3 (50%) 1 (11%) 4 (27%)
Partial 3 (50%) 7 (78%) 10 (66%)
Table 2. Comparison of magnetic resonance imaging results between patients with WHO grade II and WHO grade III/IV among 16 patients operated on for low-grade
glioma recurrence – data are reported as n (%) or median (interquartile range)
* P-values for Student t-test except for those indicated with # (χ2 test with Yates correction) or ##(Mann-Whitney U-test)
**Comparison of 15 patients
rCBV – relative cerebral blood volume
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The presence of contrast enhancement is a radiological
representation of neoangiogenesis within the tumour
that undergoes malignant transformation.
An important parameter that reflects tumour angio-
genesis is rCBV. This marker closely correlates with his-
tological grading of astrocytic tumours’ malignancy and
constitutes an important prognostic factor for outcome
[20,37-39]. Amongst the patients with malignant trans-
formation, rCBV values were significantly higher when
compared to patients without malignant transformation
(2.41 vs. 1.21, p < 0.01). No significant difference in
contrast enhancement on control MRI between these
two groups was found, although in patients with malig-
nant transformation the number of patients with con-
trast enhancement was higher (70% vs. 50%).
The higher incidence of epileptic seizures was the
main clinical sign of LGG progression. In our group,
50% of patients had higher incidence of seizures dur-
ing progression, despite antiepileptic treatment. Schmidt
et al. [33] also reported similar incidence of seizures,
with 53% of patients with recurrent LGG showing high-
er incidence of seizures. Additionally, we found that
patients with malignant transformation showed signifi-
cant deterioration of their overall performance assessed
with KPS, when compared to the remaining patients
who undergo surgery for recurrent tumour (p < 0.05).
The introduction of neuronavigation and intraoper-
ative electrophysiological monitoring into the surgical
repertoire applicable for the treatment of LGG local-
ized within eloquent areas allowed surgeons to increase
Variable WHO grading prior to reoperation Total
grade II grade III/IV
rCBV prior to initial surgery 1.28 (1.11-1.71) 1.96 (1.27-2.61) 1.60 (1.11-2.40)
rCBV prior to secondary surgery 1.21 (1.01-1.50) 2.41 (1.66-2.91) 1.81 (1.29-2.67)
P-value NS# 0.05## NS##
Tumour volume after initial surgery [cm3] 50.0 (13.8-121.3) 35.0 (20.5-52.4) 35.0 (17.9-67.4)
Tumour volume after secondary surgery* [cm3] 22.2 (14.3-88.0) 36.2 (18.2-74.7) 24.1 (14.3-88.0)
P-value NS# NS## NS##
% of tumour removal after initial surgery 77 (45-88) 70 (41-78) 74 (43-83)
% of tumour removal after secondary surgery* 79 (54-86) 62 (12-70) 70 (41-89)
P-value NS## NS# NS##
Degree of resection after initial surgery
Gross total 0 (0%) 0 (0%) 0 (0%)
Subtotal 2 (34%) 1 (10%) 3 (19%)
Partial 4 (66%) 9 (90%) 13 (81%)
Degree of resection after secondary surgery*
Gross total 0 (0%) 1 (11%) 1 (7%)
Subtotal 3 (50%) 1 (11%) 4 (27%)
Partial 3 (50%) 7 (78%) 10 (66%)
P-value NS### NS### NS###
Permanent neurological deficit after initial surgery 1 (17%) 1 (10%) 2 (12%)
Permanent neurological deficit after secondary surgery 2 (40%) 3 (33%) 5 (36%)
P-value NS### NS### NS###
Table 3. Comparison of selected variables from initial and secondary surgery in 16 patients operated on for low-grade glioma recurrence – data are reported as n (%)
or median (interquartile range)
#Student t-test for dependent variables; ##Wilcoxon pair rank test; *Comparison performed for 15 patients; ###χ2 test with Yates correction
rCBV – relative cerebral blood volume
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the extent of resection on one hand with simultaneous
limitation of permanent neurological deficits on the oth-
er. The risk of permanent neurological deficits after
surgery for LGG is relatively low at 2% to 5% [6,9,10],
even including tumours within eloquent areas of the
brain [9,20]. Sanai et al. [9] in a group of 104 patients
with insular tumours reported permanent deficits in less
than 2% of the cases (with the median of the extent of
resection at 84.5%). No significant influence of the
extent of resection on the incidence of new neurological
deficits after surgery was reported [6,10,20]. Still, for
the majority of the LGGs localized within brain elo-
quent areas, only partial resection is feasible. The resec-
tion stops whenever cortical and subcortical stimulation
signals the presence of speech or motor centres. This is
the origin of the conviction that further extension of
resection during reoperation increases the risk of new
neurological deficits. Based on that belief, some authors
suggest chemo- or radiotherapy instead of reoperation
[19,22-26]. Duffau et al., on the other hand, state that
reoperation should always be considered for patients
with recurrent LGG, even in cases when the recurrent
tumour is located within eloquent areas of the brain.
Based on their research, Duffau and his group proposed
a theory of functional reorganization of brain eloquent
centres in patients after surgery for slowly growing
tumours. According to this theory, the functional struc-
ture of the central nervous system consists of parallel,
interconnected neuronal networks that are capable of
reciprocal compensation of function in the event that
one of them is dysfunctional [40,41]. The recurrence
of the tumour residue within an eloquent area usually
expands into this area. Based on the aforementioned the-
ory, Duffau et al. state that owing to the functional plas-
ticity of the brain in response to the tumour recurrence
within a few years, the reshaping of functional tissue
occurs [42-44]. Thus, a reoperation of the tumour with-
in an eloquent area as well as the expansion of the extent
of resection without the risk of new neurological deficits
is possible [21,44]. Thus, a concept of a multistage sur-
gical approach in the treatment of LGGs within elo-
quent areas emerged based on the theory of functional
plasticity of the brain [44].
Martino et al. [21] analyzed the outcomes of 19 pa -
tients with recurrent LGG within one of the eloquent
areas of the brain. All of the patients in their group
underwent subtotal or partial resection during initial
surgery. Accordingly, all reoperations, with a single
exception of a gross total resection, were either subtotal
or partial resections. The majority of patients, i.e. 16 out
of 19 patients, showed either improvement or stabiliza-
tion of preoperative neurological deficit after reopera-
tion. According to these authors, surgery for LGG with-
in eloquent areas in several (usually two or three) stages
significantly improves survival measurements in this
group of patients. Median follow-up time in their group
averages 6.6 years. The outcomes in our group of 16 pa -
tients with LGG are similar. One should remember,
however, that our cohort included LGG cases outside
of eloquent areas of the brain (total of 5 patients). We
failed to increase the extent of resection in the majority
of the patients when compared to the initial operation.
Notably, however, reoperations did not influence the
neurological status of our patients.
Conclusions
1. The risk of tumour progression in patients after sur -
gery for LGG reaches 68%, while the risk of malig-
nant transformation within 5 years averages 47%.
2. Fifty percent of patients with LGG progression show
signs of malignant transformation of the tumour.
3. A significant factor that influences the progression of
LGG is a large volume of tumour prior to the initial
surgery.
4. The most common symptoms of LGG progression
are the increase of seizure incidence and intellectual
deterioration measured with KPS.
5. A high value of rCBV is a significant parameter that
suggests malignant transformation in patients with
LGG recurrence.
6. Reoperation of patients with LGG recurrence, even
those with tumours within eloquent areas of the brain,
does not carry higher risk of neurological deficits
when compared to the initial surgery.
7. The extent of resection during surgery for recurrent
LGG is comparable with the extents of resection
achievable during initial surgery.
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